Open Nav

NeuExcell Therapeutics

  • Zhenhua Wu, NeuExcell Therapeutics

Round A Fund raising

  • Date:Wednesday, October 17
  • Time:9:15 AM - 9:30 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:NeuExcell's mission is to cure neurodegenerative diseases through our world-leading astrocyte-to-neuron conversion platforms. NeuExcell’s proprietary and patented in vivo cell conversion technology regenerates neurons from glial cells in diseased brain/spinal cord. NeuExcell is developing a gene therapy platform to treat a variety of neurological disorders including stroke, Alzheimer’s disease, ALS, spinal cord injury, Huntington’s disease and Parkinson’s disease. Using AAV-based gene therapy, reactive glial cells inside the injured brains can be efficiently converted into functional neurons and thus lead to the restoration of lost brain functions. We have obtained solid preclinical proof-of-concept validation in mouse and monkey models of ischemic stroke. A Phase I/II clinical trial to test the safety, tolerability, behavior and imaging biomarker improvement of NXL-AAV001 gene therapy is planned to take place in 12-18 months.
  • Company
  • Company HQ City:State College
  • Company HQ Country:United States
  • Company HQ State:Pennsylvania           
  • CEO/Top Company Official:Zhenhua Wu
  • Year Founded:2016
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :NXL-AAV001
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :5
  • Total Amount Raised to Date, In All Rounds:$2million
Zhenhua Wu
NeuExcell Therapeutics